Erectile dysfunction: Monitoring response to treatment in clinical practice - Recommendations of an International Study Panel

Journal of Sexual Medicine

Volumn 4, Issue 2, 2007, Pages 448-464

  Mulhall, John ^a   Althof, Stanley E ^b   Brock, Gerald B ^c   Goldstein, Irwin ^d   Jünemann, Klaus Peter ^e   Kirby, Michael ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Center for Marital and Sexual Health of South Florida   (United States)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

^d University Clinic Kiel ^*

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

ED Treatment Satisfaction; Erectile Dysfunction; Erection Hardness; PDE5 Inhibitors; Sexual Satisfaction; Treatment Goals in ED Therapy

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CORRELATION ANALYSIS; DATA ANALYSIS; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HUMAN; MALE; MEDICAL EXPERT; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PATIENT SATISFACTION; PENIS ERECTION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOLOGY; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; SCORING SYSTEM; SELF ESTEEM; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UROLOGY;

EID: 33947159713     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00441.x     Document Type: Article

References (51)

1. Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005; 2: 848-55.
2. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6-23.
3. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Milbank AJ, Nehra A, Sharlip ID. The management of erectile dysfunction: An update. Linthicum, MD: American Urological Association Education and Research, Inc; 2005: 1.1-1.31.
4. Canadian Urological Association Guidelines Committee. Erectile dysfunction practice guidelines. Can J Urol 2002; 9: 1583-7.
5. Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. BMJ 2000; 321: 499-503.
6. Piterman L, Lording D, Sutherland P, Malcher G, Cherry D, Gillman M. Erectile dysfunction: A GP summary guide for assessment and management. East Bentleigh, Australia: Monash University; 2005.
7. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: An update. Eur Urol 2006; 49: 806-15.
8. Hatzichristou D, Rosen RC, Broderick G, Clayton A, Cuzin B, Derogatis L, Litwin M, Meuleman E, O'Leary M, Quirk F, Sadovsky R, Seftel A. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004; 1: 49-57.
9. Althof SE, O'Leary MP, Cappelleri JC, Hvidsten K, Stecher VJ, Glina S, King R, Siegel RL. Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med 2006; 3: 521-9.
10. Latini DM, Penson DF, Wallace KL, Lubeck DP, Lue TF. Longitudinal differences in psychological outcomes for men with erectile dysfunction: Results from ExCEED™. J Sex Med 2006; 3: 1068-76.
11. Latini DM, Penson DF, Wallace KL, Lubeck DP, Lue TF. Clinical and psychosocial characteristics of men with erectile dysfunction: Baseline data from ExCEED™. J Sex Med 2006; 3: 1059-67.
12. Data on file, Pfizer Inc., New York, NY. Harris Interactive. Global Better Sex Survey. 2006; 1-110.
13. Goldstein I, Jünemann KP, Mulhall JP, Stecher V. Erection hardness is critical for good sex and a healthy relationship: The Global Better Sex Survey. In: Program and abstracts of the 9th congress of the European Society for Sexual Medicine; December 3-6, 2006; Vienna, Austria. Abstract 2036.
14. Moreira ED Jr, Kim SC, Glasser D, Gingell C. Sexual activity, prevalence of sexual problems, and associated help-seeking patterns in men and women aged 40-80years in Korea: Data from the Global Study of Sexual Attitudes and Behaviors (GSSAB). J Sex Med 2006; 3: 201-11.
15. Fisher WA, Rosen RC, Eardley I, Niederberger C, Nadel A, Kaufman J, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: Understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction. J Sex Med 2004; 1: 150-60.
16. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
17. Mulhall JP, Levine LA, Jünemann KP. Erection hardness, a unifying factor for defining response in the treatment of erectile dysfunction. Urology 2006; 68 (suppl 3A): 17-25.
18. Stecher V, Collins S, Feiner C, Lording D, Gillman M. Improvement in erection quality is associated with treatment satisfaction and improved self-esteem, confidence, and sexual relationship satisfaction. Eur Urol Suppl 2006; 5: 177. Abstract 620.
19. Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: Qualitative study. BMJ 2004; 328: 1037-9.
20. Rosenberg M, Tallman C, Sailor N, Ohl D, Hazzard M. Factors affecting male sexual satisfaction in a community based general medical practice. J Sex Med 2006; 3: 224-86.
21. Min JK, Williams KA, Okwuosa TM, Bell GW, Panutich MS, Ward RP. Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. Arch Intern Med 2006; 166: 201-6.
22. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: New guidelines for sexual medicine. J Sex Med 2006; 3: 28-36.
23. Guay AT. Optimizing response to phosphodiesterase therapy: Impact of risk-factor management. J Androl 2003; 24: S59-62.
24. Data on file, Pfizer Inc., New York, NY. 2006.
25. Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, Zoccoli J, Defoy I. The prevalence of erectile dysfunction in the primary care setting: Importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006; 166: 213-9.
26. Data on file, Pfizer Inc., New York, NY. Global Consumer Attitudes & Usage Study, Wave 1: Key Findings. July 2004.
27. Willke RJ, Glick HA, McCarron TJ, Erder MH, Althof SE, Linet OI. Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol 1997; 157: 2124-8.
28. Purvis K, Egdetveit I, Christiansen E. Intracavernosal therapy for erectile failure-Impact of treatment and reasons for drop-out and dissatisfaction. Int J Impot Res 1999; 11: 287-99.
29. NIH Consensus Development Panel on Impotence. NIH Consensus Conference on Impotence. JAMA 1993; 270: 83-90.
30. Burris AS, Banks SM, Sherins RJ. Quantitative assessment of nocturnal penile tumescence and rigidity in normal men using a home monitor. J Androl 1989; 10: 492-7.
31. Rosen RC. Measurement of male and female sexual dysfunction. Curr Psychiatry Rep 2001; 3: 182-7.
32. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
33. Rosen RC, Cappelleri JC, Gendrano N III. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002; 14: 226-44.
34. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-51.
35. Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology 2000; 56: 477-81.
36. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-26.
37. Cappelleri JC, Bell SS, Althof SE, Siegel RL, Stecher VJ. Comparison between sildenafil-treated subjects with erectile dysfunction and control subjects on the Self-Esteem and Relationship questionnaire. J Sex Med 2006; 3: 274-82.
38. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): A 5-year review of research and clinical experience. Int J Impot Res 2005; 17: 307-19.
39. Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, Stecher V, Seftel AD. EDITS: Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793-9.
40. Porst H, Gilbert C, Collins S, Symonds T, Stecher V. Development and validation of the quality of erection questionnaire. J Sex Med 2006; 3: 224-86.
41. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336: 1-7.
42. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil-A comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997; 9: 187-92.
43. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-404.
44. Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD. Male Sexual Health Questionnaire (MSHQ): Scale development and psychometric validation. Urology 2004; 64: 777-82.
45. Montorsi F, Padma-Nathan H, Glina S. Erectile function and assessments of erection hardness, correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). Urology 2006; 68 (suppl 3A): 26-37.
46. Jünemann KP, Levinson IP, Creanga DL. Viagra (sildenafil citrate) 100mg helps men with erectile dysfunction achieve completely hard erections and improved sexual intercourse success, enjoyment, and satisfaction. J Sex Med 2006; 3: 224-86.
47. King R, Stecher V, Creanga D. Improved erection hardness is associated with sexual enjoyment, satisfaction, and confidence in men with erectile dysfunction treated with Viagra (sildenafil citrate). J Sex Med 2006; 3: 224-86.
48. Jünemann KP, Jacob G, Burkart M. Interrelationships among erectile function, sexual experience, satisfaction, and confidence. J Sex Med 2006; 3: 224-86.
49. Collins S, Stecher V, Wang H. Phosphodiesterase type 5 inhibitor-naive men with erectile dysfunction can achieve completely hard and fully functional erections with Viagra (cildenafil citrate). In: Program and Abstracts of the 9th Congress of the European Society for Sexual Medicine; December 3-6, 2006; Vienna, Austria. Abstract 2032.
50. Depko A, Kadioglu A, Grohmann W, Levinson IP, Carlsson M, Collins S. Erection hardness and quality correlate with erectile function, emotional well-being, and treatment satisfaction: Double-blind, placebo-controlled multinational trial of Viagra (sildenafil citrate). In: Program and Abstracts of the 9th Congress of the European Society for Sexual Medicine; December 3-6, 2006; Vienna, Austria. Abstract 2035.
51. Broderick G, Lue T. Evaluation and nonsurgical management of erectile dysfunction and priapism. In: Walsh PC, Retik AB, Vaughan ED, eds. Campbell's Urology, 8th edn. Philadelphia, PA: W.B. Saunders; 2002: 1619-70.